1. Home
  2. GOVX

as of 03-09-2026 3:59pm EST

$1.87
+$0.09
+5.06%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Founded: 2001 Country:
United States
United States
Employees: 17 City: SMYRNA
Market Cap: 4.0M IPO Year: N/A
Target Price: $200.00 AVG Volume (30 days): 129.8K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.12 - $4.40 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -35.67% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: